Press release | 15th January 2013

This is custom heading element

Only Enterprise ELN Vendor to have a “Very High” rating in more than one category

London, UK, and Boston, US, January 15, 2013 – IDBS, a global provider of innovative data management, analytics and modeling solutions, is one of only five firms out of 34 to be rated as an ELN Enterprise Vendor in Gartner’s research report titled, ‘Manufacturers Must Consider Scientific Domain Expertise During ELN Selection’, published January 11, 2013. The report, based upon hundreds of customer and vendor conversations, gave IDBS a “very high” rating in the Biology and TransMed category, a “high” rating in Chemistry, Formulation, GxP and a “medium” rating for Engineering across six of the key scientific areas.

A “Very High” rating means the vendor has excellent scientific domain capabilities and is approaching the ‘de facto’ standard. IDBS is the only Enterprise ELN Vendor to have a Very High rating in more than one category. The research is designed to be a starting source to create shortlists of vendors that best serve scientific and functional domains.

Neil Kipling, CEO and Founder of IDBS said, “We have a 20 year history of helping customers treat their R&D data as a capital asset. As the largest independent company in our sector we have moved fast and invested early to meet the needs of a newly data-centric R&D environment. For us, this report confirms that we provide an unparalleled breadth of capability in E-WorkBook. Our expanding customer base now ranges across multiple industries and scientific domains, from basic research through process development into translational research. All of them are benefitting from improved business insights and measurable efficiencies.”

For more information or a full copy of the report, please visit: www.gartner.com (requires Gartner client access login).

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.

About IDBSContact us

More news

Shutterstock 1899051346 Scaled 768x512

Beating the Capacity Crunch: Rethinking the Biopharma Supply Chain to Avoid Shortages

One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.

Read more